Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine-PR for walking and visual function in neuromyelitis optica
2013-000529-30Phase 4Completed
- Sponsor
- The Walton Centre
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of dalfampridine in neuromyelitis optica (NMO), sponsored by The Walton Centre. Primary endpoint: Walking speed improvement on Timed 25-foot walk. Started Oct 2013; status: completed.
02
Drugs
dalfampridine
03
Conditions
neuromyelitis optica (NMO)
Beyond the preview
Go deeper on 2013-000529-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000529-30.